Respiratory syncytial virus (RSV) silently claims 118,000 children's lives every year, yet until recently, the world had no vaccine to stop it. Now, after decades of scientific pursuit, RSV vaccine development has surged into a new phase—and researchers are moving boldly beyond single-shot solutions.
RSV is a familiar enemy to parents everywhere: the winter virus that fills hospital pediatric wards and keeps vulnerable infants on breathing machines. Globally, it causes an estimated 33 million acute lower respiratory infections annually in children under five, leading to over 3 million hospitalizations. The burden falls heaviest on low- and middle-income countries, where more than 99% of RSV deaths occur. Beyond childhood, the virus poses severe risks to older adults and immunocompromised individuals—a recognition that has reshaped how researchers now approach prevention.
The breakthrough that unlocked this acceleration came from understanding the RSV fusion (F) glycoprotein, particularly its prefusion form. This structural insight enabled scientists to design vaccines that mimic the virus's natural state far more effectively than earlier attempts. With several first-generation RSV vaccines now approved, the clinical pipeline has shifted dramatically. Instead of resting on that achievement, dozens of vaccine candidates are now in active trials, targeting three distinct populations: newborns (through maternal vaccination or infant monoclonal antibodies), older adults (via adjuvanted proteins and mRNA platforms), and beyond.
The vaccine landscape reflects remarkable technological diversity. Clover Biopharmaceuticals is advancing SCB-1019, a recombinant preF subunit vaccine shown in Phase 1 trials to work powerfully as a booster for older adults who previously received other approved RSV vaccines. Even more ambitiously, Clover has moved into combination vaccines—SCB-1022 (targeting both RSV and human metapneumovirus) and SCB-1033 (covering RSV, hMPV, and parainfluenza virus 3). Moderna, buoyed by success with its standalone mRNA RSV vaccine (mRESVIA), launched Phase 1 trials for mRNA-1365, a single-dose combination vaccine that protects against both RSV and hMPV using mRNA technology.
Perhaps the most innovative approach is the PIPELINE-RSV trial, a massive international adaptive study with an elegant logic: pregnant women and their newborns are randomly assigned to receive a maternal RSV vaccine alone, an infant monoclonal antibody alone, or both simultaneously. This design will answer a critical question about dual protection that traditional trials could never address.
The virus itself continues evolving, with the A.D.3 lineage of RSV-A steadily rising in prevalence since 2022, while the B.D.E.1 lineage has dominated RSV-B circulation since 2023. These shifting strain dynamics underscore why combination vaccines and broad platforms matter—they hedge against a moving target.
Real-world effectiveness remains the final frontier. Clinical trials, while demonstrating moderate to high efficacy, often underrepresent the sickest populations: people over 80, those with cardiopulmonary disease, those living in resource-limited settings. As these vaccines move from trials into clinics worldwide, tracking how they perform in the messiest real-world conditions will determine whether this scientific achievement becomes a true victory for the millions of families facing RSV each winter.